Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ampicillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TEK | Q02763 | 1/20 | 1.00 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | RARB | P10826 | 1/20 | 0.84 |
| ▸ | RARG | P13631 | 1/20 | 0.84 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.84 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.84 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.82 |
| ▸ | GLA | P06280 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ampicillin SCHEMBL3467975 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL14148474 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL9528765 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL2282070 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL13014516 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL24312533 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL13240124 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL15577318 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL22380861 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL13007617 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569013-B2 | Penicillin-G acylases | CODEXIS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120270282-A1 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8247192-B2 | Penicillin-G acylases | CODEXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20100143968-A1 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143968-A1 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010054319-A2 | PENICILLIN-G ACYLASES | CODEXIS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270282-A1 | PENICILLIN-G ACYLASES | PGLS, PNP, NAAA | KDM4E 1645/4885RECQL 474/4885HPGD 418/4885 |
| US-20100143968-A1 | PENICILLIN-G ACYLASES | PGLS, PNP, NAAA | KDM4E 1645/4885RECQL 474/4885HPGD 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.